MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

NCT04374032 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-12-24

No results posted yet for this study

Summary

An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection

Conditions

  • COVID-19 Infection

Interventions

DRUG

metenkefalin + tridecactide

ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection

DRUG

The standard of care

The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina

Sponsors & Collaborators

  • Bosnalijek D.D

    lead INDUSTRY

Principal Investigators

  • Rusmir Baljić, PhD · Clinical Center University of Sarajevo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-10-07
Completion
2020-11-03

Countries

  • Bosnia and Herzegovina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04374032 on ClinicalTrials.gov